OXB Accelerates Gene Therapy Production for Plowshare Therapies, Leveraging FDA-Approved AAV Manufacturing in North Carolina

July 26, 2026

Markets Insider UK

Overview

OXB has partnered with Plowshare Therapies to provide crucial process development and GMP manufacturing for Plowshare’s AAV gene therapy program. This collaboration leverages OXB’s FDA-approved commercial-scale facility in Durham, North Carolina, addressing the escalating global demand for specialized viral vector production and advancing innovative treatments for rare genetic diseases.

In Depth

Background

Adeno-Associated Virus (AAV) vectors are a cornerstone of gene therapy, widely favored for their high gene transfer efficiency and relatively low immunogenicity. Yet, scaling the consistent manufacturing of high-quality AAV vectors to commercial levels presents substantial technical and regulatory hurdles. With the rapid acceleration of gene therapy development, particularly for rare diseases, there’s an escalating global demand for specialized Contract Development and Manufacturing Organizations (CDMOs). OXB’s FDA-approved facility in North Carolina emerges as critical infrastructure poised to meet this demand, establishing it as an indispensable partner for innovative biotechnology firms such as Plowshare Therapies.

Key Findings

OXB, a recognized leader in the gene therapy sector, has been selected as the strategic partner to deliver comprehensive process development and Good Manufacturing Practice (GMP) manufacturing services for Plowshare Therapies’ Adeno-Associated Virus (AAV) gene therapy program. This pivotal collaboration is set to expedite innovative progress in treating rare genetic diseases.

All manufacturing operations will be centralized at OXB’s FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina. This state-of-the-art facility is instrumental in guaranteeing the safety and efficacy of gene therapies by producing high-quality AAV vectors that adhere to rigorous GMP standards. The partnership will involve bespoke process development strategies, focusing on optimizing manufacturing efficiency and yield specifically for Plowshare Therapies’ AAV candidates. This encompasses advanced optimization of cell culture conditions, refinement of vector recovery and purification protocols, and the establishment of robust quality control assays. These integrated efforts are designed to ensure a seamless progression for Plowshare Therapies from late-stage clinical trials towards potential commercialization.

Strategically, this alliance significantly reinforces OXB’s standing as a preeminent GMP manufacturing partner within the burgeoning gene therapy landscape, marking a crucial component of its long-term growth trajectory. For Plowshare Therapies, securing a consistent supply of high-quality AAV vectors represents a major milestone in advancing promising therapies for rare genetic diseases. The successful navigation of clinical trials and eventual patient delivery of therapies manufactured through this partnership are anticipated to be significant drivers for the broader gene therapy market. Stakeholders and investors will closely monitor how such strategic manufacturing alliances influence the viability and speed-to-market for cutting-edge therapeutic pipelines.

Source: https://oxb.com/news/oxb-selected-as-gmp-manufacturing-partner-to-support-manufacturing-of-plowshare-therapies-aav-gene-therapy-programme/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.